Computer modeling can cut development time and yield bioprocesses that produce safer, better quality medicines says a leading researcher.
One day, maybe soon, patients might make their own therapeutics for their own specific disease, thus realizing the potential of personalized medicine.
A European contract manufacturer says it has accelerated its upstream bioprocessing by one third, thanks to a new intensification strategy.
The alliance will leverage Rentschler Biopharma’s experience in drug substance manufacturing, including bioprocess development and API production, and Vetter’s expertise in aseptic fill and finish and secondary packaging.
As biopharma execs increasingly understand the long-term benefits of digital manufacturing, the challenge now is applying a 4.0 approach to the entire supply chain.
Bioprocessors can’t produce treatments without raw materials, such as virions. These infectious viral particles can be used in a wide range of medical products.
Researchers from Austria say they have performed the first comprehensive study of an artificial-intelligence-aided approach for bioprocess characterization.
Bottlenecks can be evaluated piecemeal, one at a time. Alternatively, they can be evaluated comprehensively and in real time by making use of data flows from well-placed sensors.
To limit cold storage, try using cell culture media that can be stored at room temperature. Thermo Fisher’s aptly named BenchStable media can perform as well as media that can’t take the heat.
Please wait while you are redirected to the right page...